January 2025

ISCTM 2025

ISCTM | 21st Annual Scientific Meeting Washington, D.C., USA | 19-21 February 2025 About the ISCTM The International Society for CNS Clinical Trials and Methodology (ISCTM) is an independent multi-disciplinary organization devoted to promoting advances in, and dissemination of, clinical research methods related to development and use of CNS therapeutics. The ISCTM accomplishes this by […]

ISCTM 2025 Read More »

Brain image

Cambridge Cognition Launches In-House Rater Training

Cambridge Cognition Launches In-House Rater Training Digital Measures that Matter Cambridge Cognition is excited to announce a new service that will help transform the quality and efficiency of brain health research. Our new Rater Training service combines with our existing digital tools to create a more streamlined and accurate way to conduct clinical studies focused

Cambridge Cognition Launches In-House Rater Training Read More »

Brain image

Actinogen Enhances Phase 2b/3 Alzheimer’s Trial with Cambridge Cognition’s Full Digital Suite

Actinogen Enhances Phase 2b/3 Alzheimer’s Trial with Our Full Digital Suite Digital Measures that Matter Cambridge Cognition is excited to announce the expansion of its partnership with Actinogen Medical Limited for the Phase 2b/3 XanaMILA Alzheimer’s disease trial. Building on the successful integration of Cambridge Cognition’s full product suite including Cognitive Assessments (CANTAB), electronic Clinical

Actinogen Enhances Phase 2b/3 Alzheimer’s Trial with Cambridge Cognition’s Full Digital Suite Read More »

Cambridge Cognition Highlights positive CANTAB® Results in research by Bristol Myers Squib

Cambridge Cognition Highlights Positive CANTAB® Results in research by Bristol Myers Squibb Digital Measures that Matter Cambridge Cognition congratulates Bristol Myers Squibb for its recent FDA approval of Cobenfy (KarXT™ or Xanomeline and Trospium) and the exciting results published recently in The American Journal of Psychiatry1 showcasing the use of CANTAB® in two Phase III

Cambridge Cognition Highlights positive CANTAB® Results in research by Bristol Myers Squib Read More »

Enhancing Patient Outcomes in ADRD: Digital Measures that Matter

Enhancing Patient Outcomes in ADRD Digital Measures that Matter As the landscape for Alzheimer’s Disease and Related Dementias (ADRD) treatment evolves, it’s crucial to align clinical research with the experiences and needs of patients and their care partners. The Digital Medicine Society’s (DiMe) Core Digital Measures of ADRD conceptual model provides a patient-centred framework for

Enhancing Patient Outcomes in ADRD: Digital Measures that Matter Read More »

Scroll to Top